Merck KGaA has revealed at its latest Capital Markets Day that it will continue to focus on its ‘Big Three’ businesses of Process Solutions and Life Science Services, new products in Healthcare and the Semiconductor Solutions arm.

By 2025, these are expected to generate about 80% of targeted sales growth, and more than 50% of total sales. The company remains on track to achieve its mid-term growth target of €25 billion that year and expects to increase sales organically by at least 6%/year on average, about €1 billion/year.